Agios Pharmaceuticals (AGIO)
(Real Time Quote from BATS)
$48.93 USD
+0.74 (1.54%)
Updated Jul 25, 2024 11:06 AM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
AGIO 48.93 +0.74(1.54%)
Will AGIO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for AGIO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AGIO
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Agios Pharmaceuticals (AGIO) Surges 6.5%: Is This an Indication of Further Gains?
AGIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Prestige Consumer Healthcare (PBH) Down 0.4% Since Last Earnings Report: Can It Rebound?
Agios (AGIO) Up 21% on Upbeat Data From 2nd Thalassemia Study
Agios (AGIO) Up 23% on Selling Brain Cancer Drug Royalty
Other News for AGIO
Agios Pharma (AGIO) Receives a Buy from Piper Sandler
Agios to Webcast Conference Call of Second Quarter 2024 Financial Results on August 1, 2024
Small-cap, buy-rated stocks with positive estimate revision factors - BofA
JPMorgan biotech analysts hold an analyst/industry conference call
Expert Ratings For Agios Pharmaceuticals